Abstract
Liraglutide (LIRA) is a GLP-1 (Glucagon Peptide Type I) analog drug widely used for treating Type 2 Diabetes Mellitus and obesity that results in improved glycemic control, satiety, and intense weight loss. Although there is evidence that central actions of LIRA mediate part of these effects, very little is known about the role of the Sympathetic Nervous System (SNS) in the loss of fat ma…